Tetsuaki Hirase
Overview
Explore the profile of Tetsuaki Hirase including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
763
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamamoto Y, Oura T, Hirase T
Diabetes Ther
. 2025 Feb;
PMID: 39951042
Introduction: The objective of this work was to assess the association of tirzepatide with changes in insulin sensitivity and beta-cell function in Japanese patients with type 2 diabetes (T2D). Methods:...
2.
Hara K, Hirase T, Pathadka S, Cai Z, Sato M, Ishida N, et al.
Diabetes Ther
. 2024 Feb;
15(4):801-817.
PMID: 38401022
Introduction: Obesity prevalence has increased in Japan in recent years. Given the strong association of obesity with poor glycemic control, and increased risk of type 2 diabetes (T2D) with central...
3.
Ishigaki Y, Hirase T, Pathadka S, Cai Z, Sato M, Takemura R, et al.
Diabetes Ther
. 2023 Oct;
15(1):245-256.
PMID: 37856046
Introduction: Recent data on the prevalence of metabolic syndrome in Japanese patients with type 2 diabetes (T2D) are limited. Methods: This retrospective, cross-sectional, observational study investigated the prevalence of metabolic...
4.
Osonoi T, Oura T, Hirase T
Diabetes Obes Metab
. 2023 Oct;
26(1):126-134.
PMID: 37794628
Aim: To evaluate glycaemic control, body weight, and safety outcomes following treatment with tirzepatide or dulaglutide in patients with type 2 diabetes (T2D) with a baseline haemoglobin (HbA1c) level of...
5.
Tsutsui H, Sakamaki H, Momomura S, Sakata Y, Kotobuki Y, Linden S, et al.
J Cardiol
. 2023 Mar;
81(6):522-530.
PMID: 36858174
Background: Several studies have reported the cost-effectiveness of sodium-glucose co-transporter 2 inhibitors in heart failure patients; however, their economic implications have not been sufficiently elucidated in Japan. Methods: A Markov...
6.
Kiyosue A, Dunn J, Cui X, Hickey A, Hirase T, Imaoka T, et al.
Diabetes Obes Metab
. 2022 Dec;
25(4):1056-1067.
PMID: 36545807
Aim: To assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and body mass index (BMI). Materials And Methods: Data of participants enrolled...
7.
Watada H, Sakamaki H, Yabe D, Yamamoto F, Murata T, Hanada K, et al.
Diabetes Ther
. 2020 Jun;
11(8):1721-1734.
PMID: 32557283
Introduction: We evaluated the cost-effectiveness of linagliptin in Japan by estimating the lifetime outcome based on clinical event rates from the Asian subpopulation of the CARMELINA trial. In CARMELINA, linagliptin...
8.
Yamamoto F, Ikeda R, Ochiai K, Hirase T, Hayashi N, Okamura T
Diabetes Ther
. 2020 Jan;
11(2):523-533.
PMID: 31933070
Introduction: International clinical trials have shown that linagliptin significantly improves glycemic control and can be used at a single dose regardless of renal function in patients with type 2 diabetes...
9.
Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova A, et al.
Clin Ther
. 2019 Sep;
41(10):2021-2040.e11.
PMID: 31561882
Purpose: The goal of this study was to assess the cost-effectiveness of empagliflozin in Japan based on the Asian subpopulation in the EMPA-REG OUTCOME trial. Methods: The trial has shown...
10.
Yasui A, Lee G, Hirase T, Kaneko T, Kaspers S, von Eynatten M, et al.
Diabetes Ther
. 2018 Mar;
9(2):863-871.
PMID: 29488164
Introduction: Empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ameliorates hyperglycemia in patients with type 2 diabetes (T2D) by inducing sustained glucosuria. Empagliflozin treatment was previously associated with a transient...